CLINICAL_TRIALS
trial_result
· 2022-04-11
Clinical Trial Update: Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma [Phase 2]
Summary
A Phase 2 trial evaluating camrelizumab in combination with CD30 CAR-T for relapsed/refractory CD30+ lymphoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Huazhong University of Science and Technology | Conditions: Lymphoma, Relapse/Recurrence | Phase 2 | Status: UNKNOWN